IRIS
LAZZARIN, ADRIANO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 3.764
NA - Nord America 3.378
EU - Europa 2.002
SA - Sud America 1.035
AF - Africa 66
Continente sconosciuto - Info sul continente non disponibili 6
OC - Oceania 1
Totale 10.252
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.272
SG - Singapore 1.536
CN - Cina 1.114
BR - Brasile 873
SE - Svezia 731
HK - Hong Kong 558
RO - Romania 268
IT - Italia 261
VN - Vietnam 249
RU - Federazione Russa 208
DE - Germania 178
GB - Regno Unito 78
FI - Finlandia 74
AR - Argentina 68
IN - India 68
CA - Canada 54
MX - Messico 41
BD - Bangladesh 37
PL - Polonia 36
ZA - Sudafrica 35
ID - Indonesia 34
EC - Ecuador 32
NL - Olanda 31
TR - Turchia 31
AT - Austria 28
JP - Giappone 25
CO - Colombia 22
IQ - Iraq 22
ES - Italia 20
IE - Irlanda 20
FR - Francia 17
PK - Pakistan 15
LT - Lituania 14
UZ - Uzbekistan 13
VE - Venezuela 13
AE - Emirati Arabi Uniti 10
UA - Ucraina 10
MA - Marocco 9
CL - Cile 8
CZ - Repubblica Ceca 6
DZ - Algeria 6
PY - Paraguay 6
SA - Arabia Saudita 6
TN - Tunisia 6
BE - Belgio 5
BO - Bolivia 5
EG - Egitto 5
EU - Europa 5
IL - Israele 5
MD - Moldavia 5
IR - Iran 4
KW - Kuwait 4
NP - Nepal 4
OM - Oman 4
UY - Uruguay 4
JO - Giordania 3
KG - Kirghizistan 3
PA - Panama 3
PE - Perù 3
TH - Thailandia 3
BB - Barbados 2
BG - Bulgaria 2
CI - Costa d'Avorio 2
DO - Repubblica Dominicana 2
GE - Georgia 2
KE - Kenya 2
KZ - Kazakistan 2
LB - Libano 2
NI - Nicaragua 2
PH - Filippine 2
PS - Palestinian Territory 2
AL - Albania 1
AM - Armenia 1
AU - Australia 1
AZ - Azerbaigian 1
BH - Bahrain 1
BN - Brunei Darussalam 1
CH - Svizzera 1
DK - Danimarca 1
GA - Gabon 1
GF - Guiana Francese 1
GT - Guatemala 1
HN - Honduras 1
HR - Croazia 1
HU - Ungheria 1
LV - Lettonia 1
MK - Macedonia 1
MN - Mongolia 1
NO - Norvegia 1
PT - Portogallo 1
QA - Qatar 1
RS - Serbia 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 10.252
Salva come PNG Salva come JPEG
Città #
Dallas 1.425
Singapore 629
Hong Kong 555
Ashburn 289
Shanghai 270
Hefei 231
Lawrence 219
Princeton 219
Beijing 165
New York 142
Milan 108
Moscow 106
Ho Chi Minh City 94
São Paulo 92
Los Angeles 83
Nuremberg 54
Helsinki 53
Hanoi 52
Boardman 44
Munich 41
Warsaw 34
Guangzhou 28
Denver 27
Orem 25
Tokyo 25
Rome 24
Pune 23
Johannesburg 22
Montreal 22
Chennai 21
Curitiba 21
Washington 21
Santa Clara 20
Atlanta 19
Seattle 19
Brooklyn 18
Mexico City 18
Belo Horizonte 17
Poplar 17
Rio de Janeiro 17
Dublin 16
Manchester 16
Stockholm 15
Turku 15
Ankara 14
Amsterdam 13
Boston 13
Brasília 13
Campinas 13
Houston 13
London 13
Shenzhen 13
Tashkent 13
The Dalles 12
Toronto 12
Vienna 12
Chicago 11
Guayaquil 11
Phoenix 11
Porto Alegre 11
Quito 11
Goiânia 10
Reston 10
Haiphong 9
Querétaro 9
Cesano Boscone 8
Hải Dương 8
Salvador 8
Betim 7
Buenos Aires 7
Da Nang 7
Frankfurt am Main 7
Istanbul 7
Kassel 7
Sorocaba 7
São José do Rio Preto 7
Tianjin 7
Charlotte 6
Columbus 6
Guarulhos 6
Ha Long 6
New Delhi 6
Nova Iguaçu 6
Quanzhou 6
Vitória 6
Belém 5
Bogotá 5
Can Tho 5
Cape Town 5
Chisinau 5
Dhaka 5
Erbil 5
Joinville 5
Miami 5
Mogi das Cruzes 5
Pouso Alegre 5
Santo André 5
Vitória da Conquista 5
Wolfhagen 5
Wuyuan 5
Totale 5.828
Salva come PNG Salva come JPEG
Nome #
The 118I reverse transcriptase mutation is the only independent genotypic predictor of virologic failure to a stavudine-containing salvage therapy in HIV-1-infected patients 1.308
Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors 133
Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19 111
A comparision of brain biopsy and CSF-PCR in the diagnosis of CNS lesions in AIDS patients 106
48 week outcomes of maraviroc-containing regimens following the genotypic or Trofile assay in HIV-1 failing subjects: the OSCAR Study 99
Candidemia in COVID-19 patients: incidence and characteristics in a prospective cohort compared to historical non-COVID-19 controls 95
Biobanking for COVID-19 research 86
Marked Decrease in Lymphocyte Count in HIV/Hepatitis C Virus (HCV)-Coinfected Patients with Advanced Liver Disease during Anti-HCV Treatment with Direct-Acting Antiviral Regimens Including Ribavirin 80
Publisher Correction: Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19 (Scientific Reports, (2020), 10, 1, (21291), 10.1038/s41598-020-78039-1) 80
HLA-associated susceptibility to AIDS: HLA B35 is a major risk factor for Italian HIV-infected intravenous drug addicts 75
Abacavir usage patterns and hypersensitivity reactions in the EuroSIDA cohort 75
Early predictors of clinical outcomes of COVID-19 outbreak in Milan, Italy 73
Circulating cathodic antigen (CCA) urine rapid test for diagnosis of Schistosoma mansoni infestation: preliminary data of a cohort study of Egyptian patients coming from an endemic area 73
HAART simplification with lopinavir/ritonavir monotherapy in HIV/HCV co-infected patients starting anti-HCV treatment: a randomised pilot study (KaMon study) 72
Analytical treatment interruption in chronic HIV-1 infection: Time and magnitude of viral rebound in adults with 10 years of undetectable viral load and low HIV-DNA (APACHE study) 71
Analysis of the faecal microbiome during analytical treatment interruption in people with chronic HIV infection and long-lasting virological suppression (APACHE study) 71
Associations of statins and antiretroviral drugs with the onset of type 2 diabetes among HIV-1-infected patients 66
Bictegravir 65
Beneficial effects of cART initiated during primary and chronic HIV-1 infection on immunoglobulin-expression of memory B-cell subsets 65
A study of cellular immunity in newborns after prevention of respiratory distress syndrome (RDS). 63
Anti-hepatitis C virus treatment may prevent the progression of liver fibrosis in non-responder human immunodeficiency virus/hepatitis C virus coinfected patients 62
A nucleoside-sparing regimen of dolutegravir plus ritonavir-boosted atazanavir in HIV-1-infected patients with virological failure: the DOLATAV study 62
Cerebrospinal fluid beta 2-microglobulin in AIDS related central nervous system involvement. 61
Switching from a Non-Protease inhibitor-Based Regimen To the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical Practice 58
Experiences with immunomodulant agents in HIV infections 58
SARS-CoV-2 IgG/IgM Rapid Test as a Diagnostic Tool in Hospitalized Patients and Healthcare Workers, at a large Teaching Hospital in northern Italy, during the 2020 COVID-19 Pandemic 58
ABC of AIDS: Treatment of infections and antiviral agents 58
Darunavir for the treatment of HIV infection 57
Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL 57
Evaluation of HIV transmission clusters among natives and foreigners living in Italy 57
Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection? 56
Dynamics of HIV-1 POL antibodies after ART in chronic HIV-1 infection 56
An observational, retrospective analysis evaluating switching to raltegravir plus abacavir/lamivudine in HIV-1-infected patients: the ORASWIRAL study 55
Cancer Risk and Use of Protease Inhibitor or Nonnucleoside Reverse Transcriptase Inhibitor-Based Combination Antiretroviral Therapy: The D:A:D Study 55
Atazanavir/ritonavir monotherapy: 96 week efficacy, safety and bone mineral density from the MODAt randomized trial 54
Point-of-care testing for hepatitis C virus infection at an Italian dental clinic: portrait of the pilot study population 53
Retrospective study on the outcome of two-drug regimens based on dolutegravir plus one reverse transcriptase inhibitor in virologically-suppressed HIV-infected patients 53
VIRO-immunological outcomes after 13-valent pneumococcal vaccination in HIV-1-infected individuals on stable virological suppression 52
Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: A sub-study of the NEAT001/ANRS143 randomized trial 52
Longitudinal evaluation of occult Hepatitis B infection in HIV-1 infected individuals during highly active antiretroviral treatment interruption and after HAART resumption 51
The impact of DAA-mediated HCV eradication on CD4+ and CD8+ T lymphocyte trajectories in HIV/HCV coinfected patients: Data from the ICONA Foundation Cohort 51
Sustained virological response after ten days of triple anti-hepatitis C virus (HCV) therapy with telaprevir plus pegylated interferon and ribavirin in an HIV/HCV co-infected cirrhotic woman 50
Long-term effect of highly active antiretroviral therapy on cervical lesions in HIV-positive women. 50
Residual viremia in HIV-infected patients who continue a two-drug or switch to a three-drug integrase strand transfer inhibitor based regimen 50
Monotherapy with atazanavir as a simplification strategy: results from an observational study. 49
Incidence and Predictors of Serological Treatment Response in Early and Late Syphilis Among People Living With HIV 49
Brief Report: Hyperbilirubinemia Is Associated With a Decreased Risk of Carotid Atherosclerosis in HIV-Infected Patients on Virological Suppression 49
Western blot in treated people with HIV-1 chronic infection: frequency of negative HIV-1 pol genes 49
HCV reinfection after HCV therapy among HIV/HCV-coinfected individuals in Europe 49
Immunological status in heroin addicts: effects of methadone maintenance treatment 48
Cannabinoid receptor 2-63 RR variant is independently associated with severe necroinflammation in HIV/HCV coinfected patients 48
Analysis of impediments to the maintenance in care of people with HIV in Italy 48
Incidence of dyslipidemia in people with HIV who are treated with integrase inhibitors versus other antiretroviral agents 48
Early Diagnosis and Linkage to Care: an Experience over 14 years of Point of Care Rapid HIV Testing 47
Early diagnosis of HIV infection in infants 47
Time spent with residual viraemia after virological suppression below 50 HIV-RNA copies/mL according to type of first-line antiretroviral regimen 47
Hepatitis delta infection among persons living with HIV in Europe 47
Brief Report: New HIV Diagnoses in PrEP-Experienced and PrEP-Naive Persons in the ICONA Cohort 46
Evolution of the E2 region of hepatitis C virus in an infant infected by mother-to-infant transmission 46
Dynamics of adaptive and innate immunity inpatients treated during primary human immunodeficiency virus infection: Results from Maraviroc in HIV Acute Infection (MAIN) randomized clinical trial 46
Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2011 46
Evolution patterns of raltegravir-resistant mutations after integrase inhibitor interruption 45
INCREASED RISK OF DEATH AMONG HIV/HCV CO-INFECTED PATIENTS WITH NON-HODGKIN'S LYMPHOMA 45
Maraviroc 150mg daily plus lopinavir/ritonavir, a nucleoside/nucleotide reverse transcriptase inhibitor-sparing regimen for HIV-infected naive patients: 48-week final results of VEMAN study 45
Benefits of a 12 week physical activity programme on muscle and bone health in people living with HIV 44
Impact of HAART on liver histology of HIV/HCV coinfected patients 44
Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients 44
Liver-related death among HIV/hepatitis C virus-co-infected individuals: Implications for the era of directly acting antivirals 44
Point-of-care testing for hepatitis C virus infection at alternative and high-risk sites: An Italian pilot study in a dental clinic 43
Evolving treatment implementation among HIV- infected pregnant women and their partners: Results from a national surveillance study in Italy, 2001-2015 43
Long-term suppression of viral replication in HIV-related lymphoma survivors: a case-control study 43
Zidovudine and frequency of HIV-induced diffuse leukoencephalopathy 42
Homeostatic model assessment for insulin resistance index trajectories in HIV-infected patients treated with different first-line antiretroviral regimens 42
Drop in CD4+ Counts Below 200 Cells/μL After Reaching (or Starting From) Values Higher than 350 Cells/μL in HIV-Infected Patients With Virological Suppression 42
Evaluation of HIV-DNA and residual viremia levels through week 96 in HIV-infected individuals who continue a two-drug or switch to a three-drug integrase strand transfer inhibitor-based regimen 42
Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: A prospective international cohort study 41
Estimated glomerular filtration rate trajectories in HIV-infected subjects treated with different ritonavir-boosted protease inhibitors and tenofovir disoproxil fumarate or abacavir 41
Naive HIV/HCV-coinfected patients have higher intrahepatic pro-inflammatory cytokines than coinfected patients treated with antiretroviral therapy 40
Cytomegalovirus pneumonia in AIDS patients: value of cytomegalovirus culture from BAL fluid and correlation with lung disease 40
Immune recovery and T cell subset analysis during effective treatment with maraviroc 40
The Less Drugs Regimens (LDRs) therapy approach in HIV-1: an Italian expert panel perspective for the long-term management of HIV-1 infection. 40
Hyaluronic Acid Levels Predict Risk of Hepatic Encephalopathy and Liver-Related Death in HIV/Viral Hepatitis Coinfected Patients 40
Morphogenesis, evolution and prognostic significance of lymphatic tissue lesions in HIV infection 40
Clinical and epidemiological aspects of the first 50 cases of AIDS in Milan 40
Clinical, virologic, and immunologic outcomes in lymphoma survivors and in cancer-free, HIV-1-infected patients: a matched cohort study. 40
Survival of HIV-1 Infected Multidrug-Resistant Patients Recycling Enfuvirtide After a Previous Failure 39
Risk of HIV-related diseases in heterosexuals importing infection from Zaire 38
Long-lasting CCR5 internalization by antibodies in a subset of long-term non progressors: a possible protective effect against disease progression 38
Determination of human papillomavirus (HPV) load and type in high-grade cervical lesions surgically resected from HIV-infected women during follow-up of HPV infection. 38
Cytomegalovirus infection of the central nervous system in patients with aids: Diagnosis by DNA amplification from cerebrospinal fluid 38
Reduced frequency of HIV-induced brain lesions in AIDS patients treated with zidovudine 38
GB Virus C and Survival in Persons with HIV Infection 37
Italian Guidelines for the Use of Antiretroviral Agents and the Diagnostic-clinical Management of HIV-1 Infected Persons 37
Italian consensus statement on management of HIV-infected individuals with advanced disease naïve to antiretroviral therapy 37
Presence of multiple genotypes in subjects with HPV-16 infection is highly associated with anal squamous intraepithelial lesions in HIV-1 infected males 37
Virological response and retention in care according to time of starting ART in Italy: Data from the Icona Foundation Study cohort 37
LONG-TERM SURVIVAL AMONG HIV-1 INFECTED PATIENTS WITH AIDS AND NON AIDS RELATED MALIGNANCIES 37
THE EFFECT OF HIV-1 IN DECREASING MITOCHONDRIAL DNA IN PERIPHERAL BLOOD MONONUCLEAR CELLS OVERCOMES THE TOXIC EFFECT OF ANTIRETROVIRAL THERAPY (ART) 37
Incidence of hypertension in people with HIV who are treated with integrase inhibitors versus other antiretroviral regimens in the RESPOND cohort consortium 36
Pharmacokinetics of the raltegravir/maraviroc/etravirine combination 36
Totale 6.572
Salva come PNG Salva come JPEG
Categoria #
all - tutte 85.647
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 85.647
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202184 0 0 0 0 0 14 11 57 1 0 1 0
2021/2022145 0 0 0 77 6 8 8 13 10 7 3 13
2022/20231.203 483 292 102 7 10 125 33 85 48 1 11 6
2023/2024605 7 29 81 49 45 137 13 68 0 15 80 81
2024/20253.101 375 58 37 81 83 256 711 232 487 360 162 259
2025/20265.170 718 880 1.425 1.260 633 254 0 0 0 0 0 0
Totale 10.519